Last reviewed · How we verify
CRTE7A2-01 TCR-T cell therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CRTE7A2-01 TCR-T cell therapy (CRTE7A2-01 TCR-T cell therapy) — Corregene Biotechnology Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CRTE7A2-01 TCR-T cell therapy TARGET | CRTE7A2-01 TCR-T cell therapy | Corregene Biotechnology Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CRTE7A2-01 TCR-T cell therapy CI watch — RSS
- CRTE7A2-01 TCR-T cell therapy CI watch — Atom
- CRTE7A2-01 TCR-T cell therapy CI watch — JSON
- CRTE7A2-01 TCR-T cell therapy alone — RSS
Cite this brief
Drug Landscape (2026). CRTE7A2-01 TCR-T cell therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/crte7a2-01-tcr-t-cell-therapy. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab